Looking for undervalued stocks? Check out three top undervalued stocks to buy now in May, 2025 to boost your portfolio.

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

Eli Lilly and Co (LLY) reports a 45% revenue increase, driven by key products and strategic advancements in diabetes and ...

Revenue grew 45% compared to Q1 of 2024. Our key products defined as Ebglyss, Jaypirca, Kisunla, Mounjaro, Omvoh, Verzenio and Zepbound grew by more than $4 billion and now account for $7.5 ...

Where will Eli Lilly be in five years? Despite Lilly's huge success in treating diabetes and obesity, it's not the leader in those markets. That honor belongs to Novo Nordisk ( NVO 1.36%), which sells ...

Newer products (products launched from 2022 onwards) like Ebglyss, Jaypirca and Omvoh are likely to have contributed to sales growth. Sales of the new Alzheimer’s drug Kisunla (donanemab ...

1 The Company defines Key Products as Ebglyss, Jaypirca, Kisunla, Mounjaro, Omvoh, Verzenio, and Zepbound. First-Quarter Non-GAAP Measures On a non-GAAP basis, Q1 2025 gross margin increased 47% ...

Newer products (products launched from 2022 onwards) like Ebglyss, Jaypirca and Omvoh are likely to have contributed to sales growth. Sales of the new Alzheimer’s drug Kisunla (donanemab ...

Revenue in Q1 2025 increased 45% to $12.73 billion driven by volume growth from Mounjaro and Zepbound. <li /> Pipeline progress included ...

These include Kisunla in Alzheimer's disease; Ebglyss, an eczema treatment; and ulcerative colitis therapy Omvoh. Further, Eli Lilly has an incredibly deep pipeline. Yes, here too, the company's ...